The $2.0M director-backed financing is a positive signal of insider commitment and provides 4-6 quarters of runway for BETR-001 preclinical work, but the company remains a high-risk pre-revenue biotech. Traders should watch for IND filing progress or a partnership deal on the interferon assets; without these catalysts, dilution risk remains high given 45M warrants outstanding.
Price Chart
Executive Summary
BetterLife Pharma's 6-K filing for the fiscal Q1 ended April 30, 2026 shows no revenue, a widened net loss of $612,622 (vs $207,054 a year ago), and a working capital deficit of $6.4M. However, the filing also discloses a $2.0M convertible debenture financing from a director closed on June 21, 2026, earmarked for IND-enabling work on the lead BETR-001 program. The funding extends the cash runway and de-risks near-term preclinical milestones, but the company remains pre-revenue with substantial doubt about going concern.
Key Facts
- No revenue reported; net loss of $612,622 for Q1 2026, up from $207,054 in Q1 2025.
- Working capital deficiency of $6,406,691 at April 30, 2026.
- Accumulated deficit reached $120,700,750.
- Closed a $2.0M convertible debenture private placement from a director on June 21, 2026 (10% interest, convertible at $0.10/unit, maturity June 1, 2027).
- Lead drug candidate BETR-001 (2-bromo-LSD) is at preclinical stage; GMP manufacturing and IND-enabling toxicology studies ongoing.
- Issued 6.05M stock options during the quarter, driving a $100,500 increase in share-based payment expense.
- Outstanding shares: 161,887,025; warrants: 45,209,530; stock options: 15,800,000 as of June 26, 2026.
- A $367,428 judgment against the company related to a former subsidiary's lease guarantee remains outstanding.
Financial Impact
Net loss widened by $405,568 YoY to $612,622; working capital deficit of $6.4M; $2.0M new financing provides near-term liquidity but does not change the fundamental cash-burn trajectory.
Risk Factors
- Going concern uncertainty; substantial doubt about ability to continue operations without additional funding.
- No approved products or revenue; all candidates are preclinical.
- Massive share dilution from 45M outstanding warrants and 15.8M stock options.
- Outstanding legal judgment of $367,428 plus punitive damages.
- Single-product dependency on BETR-001 (2-bromo-LSD) with no guarantee of clinical success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001477932-26-004038 |
| Document: betrf_ex991.htm | 0001477932-26-004038 |
| Document: betrf_6k.htm | 0001477932-26-004038 |
| Document: betrf_ex993.htm | 0001477932-26-004038 |
| Document: 0001477932-26-004038-index-headers.html | 0001477932-26-004038 |
| Document: 0001477932-26-004038-index.html | 0001477932-26-004038 |
| Document: 0001477932-26-004038.txt | 0001477932-26-004038 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 26d ago | 6-K | $0.2410 $0.1920 | ▼ −20.33% | ▼ −22.25% | $0.1685 (−30.08%) |
Sep 22, 2026 4w ago | SC 13G | $0.2400 $0.2410 | ▲ +0.42% | ▲ +1.09% | $0.1685 (−29.79%) |
Sep 15, 2026 5w ago | 6-K | $0.2740 $0.2217 | ▼ −19.09% | ▼ −19.91% | $0.1685 (−38.50%) |
Sep 11, 2026 6w ago | 6-K | $0.2300 $0.2550 | ▲ +10.87% | ▲ +11.09% | $0.1685 (−26.74%) |
Aug 24, 2026 9w ago | 6-K | $0.2240 $0.2195 | ▼ −2.01% | ▼ −2.48% | $0.1685 (−24.78%) |
Jun 26, 2026 17w ago | 6-K | $0.1110 $0.1310 | ▲ +18.02% | ▲ +15.85% | $0.1685 (+51.80%) |
Apr 13, 2026 27w ago | 6-K | $0.0410 $0.0480 | ▲ +17.07% | ▲ +13.78% | $0.1685 (+310.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers